Weight loss & GLP-1 Protocols

About these protocols

Incretin-class medicines (GLP-1, GIP and glucagon agonists) are escalated in steps because gastrointestinal side effects are dose-related. Label and trial schedules are reproduced only from FDA labels and published trials.

Label and trial schedules

Semaglutide 2.4 mg: Wegovy Label Escalation Schedule (2026)Wegovy label: 0.25 mg weekly for 4 weeks, then 0.5, 1, 1.7 mg, reaching 2.4 mg at week 17. Wegovy HD 7.2 mg only after 4+ weeks at 2.4 mg. Sources linked.
Tirzepatide 15 mg: Zepbound Label Escalation Schedule (2026)Zepbound label: 2.5 mg weekly for 4 weeks, then 5 mg; increase by 2.5 mg after at least 4 weeks per step. Maintenance 5, 10 or 15 mg; maximum 15 mg. Sources linked.
Retatrutide 12 mg in Phase 3: TRIUMPH Escalation ScheduleTRIUMPH-2/3 started retatrutide at 2 mg weekly and stepped up every 4 weeks (2 → 4 → 6 → 9 → 12 mg). Retatrutide is investigational and not approved. Sources linked.

Reconstitution math by vial size (12)

Evidence behind each compound

FDA status and research volume for every compound with a page in this category (PubMed and ClinicalTrials.gov, checked 2026-10-19).
Compound	Status	PubMed records	Registered trials
Semaglutide	FDA-approved	5,707	788
Tirzepatide	FDA-approved	2,637	303
Retatrutide	Investigational	202	33
Survodutide	Investigational	87	29
Mazdutide	Investigational	54	43
AICAR	Not approved (research only)	2,433	0
L-carnitine	FDA-approved	300	313
MOTS-c	Not approved (research only)	259	5
5-Amino-1MQ	Not approved (research only)	3	0
Cagrilintide	Investigational	103	44
Tesamorelin	FDA-approved	95	24
AOD-9604	Not approved (research only)	22	0

A large PubMed count can reflect a natural hormone or a related drug rather than the research product itself; open each profile for what the studies actually tested.

Related peptide profiles

Semaglutide Tirzepatide Retatrutide Survodutide Mazdutide AICAR L-carnitine MOTS-c 5-Amino-1MQ Cagrilintide Tesamorelin AOD-9604 All weight loss & glp-1 peptides